Pravastatin Actavis

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Pravastatin sodium 20mg;  

Disponibbli minn:

Teva Pharma (New Zealand) Limited

INN (Isem Internazzjonali):

Pravastatin sodium 20 mg

Dożaġġ:

20 mg

Għamla farmaċewtika:

Tablet

Kompożizzjoni:

Active: Pravastatin sodium 20mg   Excipient: Croscarmellose sodium Iron oxide yellow Lactose monohydrate Light magnesium oxide Magnesium stearate Microcelac 100 Povidone

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Biocon Limited

Indikazzjonijiet terapewtiċi:

In hypercholesterolemic patients without clinically evident coronary heart disease, Pravastatin Actavis is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. Pravastatin Actavis is indicated for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. Pravastatin Actavis is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, Alu-Alu blister pack with cardboard carton secondary packaging - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture

Data ta 'l-awtorizzazzjoni:

2014-01-20